CN115697980B - 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑 - Google Patents

作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑 Download PDF

Info

Publication number
CN115697980B
CN115697980B CN202180043311.4A CN202180043311A CN115697980B CN 115697980 B CN115697980 B CN 115697980B CN 202180043311 A CN202180043311 A CN 202180043311A CN 115697980 B CN115697980 B CN 115697980B
Authority
CN
China
Prior art keywords
group
alkyl
phenyl
atom
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180043311.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115697980A (zh
Inventor
N·施梅斯
U·勒恩
D·基尔霍夫
K·皮特森
T·T·U·阮
M·格雷斯
N·沃尔贝克
U·伯默
B·贝德
D·斯托凯特
D·科泽蒙德
R·奥夫林加
C·林克
K·诺瓦克-雷皮尔
U·罗森特雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to CN202510268418.9A priority Critical patent/CN120093741A/zh
Priority to CN202510268414.0A priority patent/CN120093739A/zh
Priority to CN202510268420.6A priority patent/CN120093742A/zh
Priority to CN202510268417.4A priority patent/CN120093740A/zh
Publication of CN115697980A publication Critical patent/CN115697980A/zh
Application granted granted Critical
Publication of CN115697980B publication Critical patent/CN115697980B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202180043311.4A 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑 Active CN115697980B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202510268418.9A CN120093741A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268414.0A CN120093739A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268420.6A CN120093742A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268417.4A CN120093740A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171280 2020-04-24
EP20171280.9 2020-04-24
PCT/EP2021/060167 WO2021214019A1 (en) 2020-04-24 2021-04-20 Substituted aminothiazoles as dgkzeta inhibitors for immune activation

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202510268417.4A Division CN120093740A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268420.6A Division CN120093742A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268418.9A Division CN120093741A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268414.0A Division CN120093739A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑

Publications (2)

Publication Number Publication Date
CN115697980A CN115697980A (zh) 2023-02-03
CN115697980B true CN115697980B (zh) 2025-03-21

Family

ID=70464845

Family Applications (6)

Application Number Title Priority Date Filing Date
CN202180043311.4A Active CN115697980B (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268414.0A Pending CN120093739A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268417.4A Pending CN120093740A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202180037365.XA Active CN115697979B (zh) 2020-04-24 2021-04-20 作为用于免疫激活的dgkzeta抑制剂的取代的氨基噻唑类
CN202510268418.9A Pending CN120093741A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268420.6A Pending CN120093742A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202510268414.0A Pending CN120093739A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268417.4A Pending CN120093740A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202180037365.XA Active CN115697979B (zh) 2020-04-24 2021-04-20 作为用于免疫激活的dgkzeta抑制剂的取代的氨基噻唑类
CN202510268418.9A Pending CN120093741A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN202510268420.6A Pending CN120093742A (zh) 2020-04-24 2021-04-20 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑

Country Status (32)

Country Link
US (3) US20230167103A1 (https=)
EP (2) EP4139286B1 (https=)
JP (3) JP7663603B2 (https=)
KR (1) KR20230005247A (https=)
CN (6) CN115697980B (https=)
AR (1) AR121929A1 (https=)
AU (1) AU2021261524A1 (https=)
CA (2) CA3180670A1 (https=)
CL (1) CL2022002919A1 (https=)
CO (1) CO2022014876A2 (https=)
CR (1) CR20220536A (https=)
DK (1) DK4139286T3 (https=)
DO (1) DOP2022000223A (https=)
EC (1) ECSP22080829A (https=)
ES (1) ES3029140T3 (https=)
FI (1) FI4139286T3 (https=)
GE (2) GEAP202416095A (https=)
HR (1) HRP20250519T1 (https=)
HU (1) HUE071024T2 (https=)
IL (1) IL297499A (https=)
JO (1) JOP20220267A1 (https=)
LT (1) LT4139286T (https=)
MA (1) MA59379B1 (https=)
MX (1) MX2022013388A (https=)
PE (1) PE20230322A1 (https=)
PH (1) PH12022552828A1 (https=)
PL (1) PL4139286T3 (https=)
PT (1) PT4139286T (https=)
RS (1) RS66889B1 (https=)
SI (1) SI4139286T1 (https=)
TW (1) TWI894261B (https=)
WO (2) WO2021214019A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CN115697980B (zh) 2020-04-24 2025-03-21 拜耳公司 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CR20230415A (es) 2020-11-30 2023-09-08 Kotobuki Pharmaceutical Co Ltd Compuesto de heteroarilcarboxamida
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN119654312A (zh) * 2022-08-08 2025-03-18 百时美施贵宝公司 用作t细胞活化剂的取代的四唑基化合物
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
WO2024200410A1 (en) 2023-03-31 2024-10-03 Bayer Aktiengesellschaft Microcrystalline forms of (r)-2-(n-[4-amino-5-(4-methoxybenzoyl)thiazol-2-yl]-4-fluoroanilino)propanamide and processes for their preparation
CN120826393A (zh) * 2023-04-06 2025-10-21 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的噻唑类化合物
WO2024235203A1 (zh) * 2023-05-15 2024-11-21 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2025061020A1 (zh) * 2023-09-21 2025-03-27 楚浦创制（武汉）医药科技有限公司 苯并五元杂环衍生物及其制备方法与应用、药物组合物
WO2025067360A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 一种DGKzeta拮抗剂及其在医药上的应用
WO2025082274A1 (zh) * 2023-10-17 2025-04-24 楚浦创制（武汉）医药科技有限公司 硫代羰基化合物及其应用
WO2025082460A1 (zh) * 2023-10-20 2025-04-24 上海先祥医药科技有限公司 二酰基甘油激酶抑制剂化合物及其应用
WO2025167814A1 (zh) * 2024-02-06 2025-08-14 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2026068294A1 (en) * 2024-09-24 2026-04-02 Bayer Aktiengesellschaft Improved nanoseeding process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019133445A1 (en) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
WO2020006016A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
RU2324685C2 (ru) 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
US20050137239A1 (en) 2003-12-17 2005-06-23 Hines Michelle D. Thiazole derivatives
US20080146585A1 (en) 2004-04-20 2008-06-19 Ab Science Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
AU2005236055B2 (en) 2004-04-20 2011-10-06 Transtech Pharma, Llc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
WO2005102346A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating fibrosis
JP2007533731A (ja) 2004-04-23 2007-11-22 アブ サイエンス マラリア原虫関連の疾病を処置するためのｃ−ｋｉｔ阻害剤の使用法
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
EP1742627A4 (en) 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
JP2007538064A (ja) 2004-05-18 2007-12-27 アブ サイエンス 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007022415A2 (en) 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
KR100903974B1 (ko) 2007-09-27 2009-06-25 한국화학연구원 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
AP2010005480A0 (en) 2008-06-03 2010-12-31 Siga Technologies Inc Small molecule inhibitors for the treatment or prevention of denque virus infection.
JP5322296B2 (ja) 2008-08-20 2013-10-23 日本曹達株式会社 テトラゾイルオキシム誘導体を含む植物病害防除剤の使用方法
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2013033037A2 (en) 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
CN103058949A (zh) 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
CN103159695B (zh) 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
GB201307233D0 (en) 2013-04-22 2013-05-29 Vib Vzw Compounds and uses thereof
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
CN106109467B (zh) 2016-06-20 2020-04-17 中国药科大学 三类羧基取代芳香化合物在耐吡嗪酰胺结核病及结核病治疗中的医药用途
WO2018089902A1 (en) 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
WO2021028382A1 (en) 2019-08-12 2021-02-18 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
WO2021091885A2 (en) 2019-11-04 2021-05-14 Alector Llc Siglec-9 ecd fusion molecules and methods of use thereof
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
KR20230005289A (ko) 2020-04-24 2023-01-09 베링거 인겔하임 인터내셔날 게엠베하 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
CN115697980B (zh) 2020-04-24 2025-03-21 拜耳公司 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019133445A1 (en) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
WO2020006016A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators

Also Published As

Publication number Publication date
CN120093739A (zh) 2025-06-06
EP4139287B1 (en) 2025-02-26
CA3180819A1 (en) 2021-10-28
DOP2022000223A (es) 2022-11-15
TW202200552A (zh) 2022-01-01
EP4139287C0 (en) 2025-02-26
TWI894261B (zh) 2025-08-21
WO2021214019A1 (en) 2021-10-28
CO2022014876A2 (es) 2023-03-17
CR20220536A (es) 2023-01-17
JOP20220267A1 (ar) 2022-10-24
JP2023522251A (ja) 2023-05-29
CN120093742A (zh) 2025-06-06
MA59379B1 (fr) 2025-04-30
CN120093740A (zh) 2025-06-06
PH12022552828A1 (en) 2023-11-20
PT4139286T (pt) 2025-05-21
ES3029140T3 (en) 2025-06-23
JP2025120943A (ja) 2025-08-18
CL2022002919A1 (es) 2023-03-31
AR121929A1 (es) 2022-07-27
LT4139286T (lt) 2025-05-12
SI4139286T1 (sl) 2025-06-30
EP4139286A1 (en) 2023-03-01
CN115697980A (zh) 2023-02-03
US20230167078A1 (en) 2023-06-01
CA3180670A1 (en) 2021-10-28
RS66889B1 (sr) 2025-07-31
ECSP22080829A (es) 2022-11-30
EP4139287A1 (en) 2023-03-01
US11964953B2 (en) 2024-04-23
WO2021214020A1 (en) 2021-10-28
BR112022019057A2 (pt) 2022-11-08
HRP20250519T1 (hr) 2025-06-20
FI4139286T3 (fi) 2025-05-07
US20230139936A1 (en) 2023-05-04
KR20230005247A (ko) 2023-01-09
DK4139286T3 (da) 2025-05-05
EP4139286B1 (en) 2025-02-26
HUE071024T2 (hu) 2025-07-28
PL4139286T3 (pl) 2025-08-11
CN115697979A (zh) 2023-02-03
GEP20257731B (en) 2025-02-10
MX2022013388A (es) 2022-11-30
CN115697979B (zh) 2025-06-24
US20230167103A1 (en) 2023-06-01
JP7663603B2 (ja) 2025-04-16
GEAP202416095A (en) 2024-08-26
PE20230322A1 (es) 2023-02-22
CN120093741A (zh) 2025-06-06
JP2023522250A (ja) 2023-05-29
IL297499A (en) 2022-12-01
AU2021261524A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CN115697980B (zh) 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
CN115210238B (zh) 作为用于免疫激活的DGKα抑制剂的取代的氨基喹诺酮类
CA2996318C (en) Heteroaryl compounds as irak inhibitors and uses thereof
US20230062100A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
JP6704398B2 (ja) ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
JP2025143330A (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
EP3638670B1 (en) Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
ES2902799T3 (es) Inhibidores de indoleamina 2,3-dioxigenasa y/o de triptófano 2,3-dioxigenasa
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
HK40081016A (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
HK40081016B (zh) 作为dgkzeta抑制剂用於免疫活化的取代的氨基噻唑
BR112022019057B1 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune, seus usos, composição e combinação farmacêuticas, e kit
EA048085B1 (ru) Замещенные аминотиазолы в качестве ингибиторов dgkzeta для иммунной активации
WO2025021997A1 (en) New map4k1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081016

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: N. Schemes

Inventor after: D. Stokate

Inventor after: D. Cozemond

Inventor after: R. Ovlinga

Inventor after: C. Link

Inventor after: NOWAK-REPPEL KATRIN

Inventor after: U. Rosentlet

Inventor after: U. Ryan

Inventor after: D. Kirchhoff

Inventor after: K. Peterson

Inventor after: T.T.U.Ruan

Inventor after: Goerres Markus

Inventor after: N. Walbeck

Inventor after: U. Bermer

Inventor after: B. Bedd

Inventor before: N. Schemes

Inventor before: D. Stokate

Inventor before: D. Cozemond

Inventor before: R. Ovlinga

Inventor before: C. Link

Inventor before: NOWAK-REPPEL KATRIN

Inventor before: U. Ryan

Inventor before: D. Kirchhoff

Inventor before: K. Peterson

Inventor before: T.T.U.Ruan

Inventor before: Goerres Markus

Inventor before: N. Walbeck

Inventor before: U. Bermer

Inventor before: B. Bedd

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant